Augmented Clearance of Nivolumab Is Associated with Renal Functions in Chronic Renal Disease Model Rats
Abstract
The clinically approved dose of nivolumab is 240 mg every 2 weeks. However, previous studies have shown that baseline nivolumab clearance (CL) is associated with treatment outcomes in patients with solid cancers, thus motivating researchers to identify prognostic factors and indices influencing nivolumab CL. This study used chronic kidney disease model rats to investigate whether chronic renal impairment affected nivolumab CL and explored the...
Paper Details
Title
Augmented Clearance of Nivolumab Is Associated with Renal Functions in Chronic Renal Disease Model Rats
Published Date
Aug 4, 2021
Volume
50
Issue
6
Pages
822 - 826
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History